左西孟旦与米力农治疗急性失代偿性心力衰竭患者疗效与安全性对比观察  

Comparative observation of efficacy and safety of Levosimendan and Milrinone in the treatment of patients with acute decompensated heart failure

作　　者：闫鹏鹏 刘明涛[2] YAN Pengpeng;LIU Mingtao(Department of Dispensary,Lubei Technician College,Shandong Province,Binzhou256610,China;Department of General Practice,Binzhou People's Hospital,Shandong Province,Binzhou256612,China)

机构地区：[1]鲁北技师学院医务室,山东滨州256610 [2]山东省滨州市人民医院全科医学科,山东滨州256612

出　　处：《中国当代医药》2023年第28期66-69,共4页China Modern Medicine

摘　　要：目的比较左西孟旦与米力农治疗急性失代偿性心力衰竭患者的效果与安全性。方法选取2020年6月至2021年12月滨州市人民医院住院的54例急性失代偿期心力衰竭患者作为研究对象,采用随机数字表法将其分成试验组与对照组,每组27例。两组患者在接受常规心力衰竭治疗基础上分别用药,试验组在常规治疗基础上加用左西孟旦治疗,而对照组加用米力农治疗。比较两组患者治疗前及治疗后24 h的左室射血分数(LVEF)、每搏量(SV)、心输出量(CO)、左室舒张期E峰/A峰比值(E/A),并测定治疗前及治疗5 d后脑钠肽(BNP)、呼吸困难程度评估、临床症状改善情况,以及药物相关不良事件。结果治疗后,两组患者LVEF、SV、CO、E/A值均高于本组治疗前,试验组SV、CO高于对照组,差异有统计学意义(P<0.05);两组患者治疗后的LVEF、E/A值比较,差异无统计学意义(P>0.05)。治疗后,两组患者BNP值均低于本组治疗前,试验组的BNP值低于对照组,差异有统计学意义(P<0.05)。治疗24 h后,两组患者呼吸困难评分均低于本组治疗前,试验组呼吸困难评分低于对照组,差异有统计学意义(P<0.05)。治疗5 d后,两组患者全身症状评分均低于本组治疗前,试验组全身症状评分低于对照组,差异有统计学意义(P<0.05)。两组患者药物不良反应总发生率比较,差异无统计学意义(P>0.05)。结论左西孟旦对急性失代偿心力衰竭患者疗效确切,在缓解患者症状、改善血流动力学等方面均优于米力农。Objective To compare the efficacy and safety of Levosimendan and Milrinone in the treatment of patients with acute decompensated heart failure.Methods A total of 54 patients with acute decompensated heart failure hospitalized in Binzhou People's Hospital from June 2020 to December 2021 were selected as the research objects,they were divided into experimental group and control group according to random number table method,with 27 cases in each group.Patients in the two groups were treated separately on the basis of conventional heart failure treatment,the experimental group was treated with Levosimendan on the basis of conventional treatment,and the control group was treated with Milrinone.Left ventricular ejection fraction(LVEF),stroke volume(SV),cardiac output(CO),left ventricular diastolic E-peak/A-peak ratio(E/A)in diastolic period were compared between the two groups before and 24 h after treatment,the brain natriuretic peptide(BNP),dyspnea degree assessment,clinical symptom improvement before and 5 d after treatment,drug-related adverse events were measured.Results After treatment,LVEF,SV,CO and E/A in two groups were higher than those before treatment,and SV and CO in experimental group were higher than those of control group,the differences were statistically significant(P<0.05).There were no significant differences in LVEF and E/A between the two groups after treatment(P>0.05).After treatment,BNP in two groups was lower than that before treatment,and BNP in experimental group was lower than that of control group,the differences were statistically significant(P<0.05).After 24 h of treatment,dyspnea scores in two groups were lower than those before treatment,and dyspnea score in experimental group was lower than that of control group,with statistical significances(P<0.05).After 5 d of treatment,the systemic symptom scores of two groups were lower than those before treatment,and the systemic symptom score of experimental group was lower than that of control group,with statistical significances(P<0.05).There

关 键 词：心力衰竭 左西孟旦 米力农 疗效 安全性 

分 类 号：R541.6[医药卫生—心血管疾病]